Data base for:

  • Conferences
  • Research funding opportunities
  • Competitions / Awards

Register for free and add any data by yourself!

See How to

Filter conferences

 
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
 
      
      
 
      
 
      
      
      
      
      
      
      
      
      
      
Ophthalmic Drugs 2018

Ophthalmic Drugs 2018

Categories

Date of beginning

Monday, 26 November 2018

Duration

2 days

Deadline for abstracts

-

City

Greater London

Country

United Kingdom

Contact

Pav Solanki

E-Mail

This email address is being protected from spambots. You need JavaScript enabled to view it.

Expected participants

0

Participants

0

Memo

As the global population ages, the incidence of ophthalmic disorders continues to grow, and thus the interest of pharmaceutical and biotech companies is increasingly focused towards innovation of novel approaches for the development of ophthalmic drugs, driving the growth of the global ophthalmic drug market, which is projected to reach £30 billion by 2023.



Building on last year's success, this must-attend conference will bring together industry experts to discuss and analyse the latest advancements and challenges within ophthalmic drug development and delivery. Some notable areas of interest have been neuroprotection in ophthalmology, advancements in gene therapy, AMD clinical trial updates, and novel approaches for delivery of ocular drugs. The two-day event will also feature two interactive workshops on the 28th November 2018, led by twoXAR and Aston University.



This Year's Agenda Highlights Include:



- Discover recent advances in the treatment of glaucoma

- Gain insight into the first FDA-approved gene therapy, developed for the treatment of inherited retinal dystrophy

- Discuss case studies on novel non-invasive and site-specific drug delivery strategies

- Examine the applications of artificial intelligence in drug discovery

- Explore use of biomarkers and surrogate end-points from a regulatory perspective



Chairs for 2018:



- Mitchell de long, Vice President, Chemistry, Aerie Pharmaceuticals

- Naj Sharif, Executive Director and Head, Global Alliances and External Research, Santen



Key Speakers:



- Majid Anderesi, Associate Group Clinical Director, Ophthalmology, Roche

- Caroline Barelle, CEO, Elasmogen

- Victor Chong, Global Head of Ophthalmology, Boehringer Ingelheim

- Daniel Chung, Clinical Ophthalmic Lead, Spark Therapeutics

- Aniz Girach, Chief Medical Officer, Nightstar Therapeutics

- Peter Morgan-Warren, Medical Assessor, Licensing Division, MHRA

- David Silverman, Clinical Director, Ophthalmology, Roche



View the full agenda: www.ophthalmicdrugs.com/evv.



Price:

Standard Price (Early Bird Rates Available Online): GBP 1499.0.



Time: 8:30 am to 5:30 pm.



Venue details: Copthorne Tara Hotel London Kensington, Scarsdale Place, Greater London, W8 5SY, United Kingdom.